Samsung is a name readily associated with smartphones and wide-screen TVs, but the company has been broadening its horizons in recent years.
It is now building a reputation as a contract manufacturer of complex medicines to treat diseases such as cancer and rheumatoid arthritis.
It has diversified into healthcare under its Samsung Biologics and Samsung Bioepis brands, reducing its reliance on mobile phones and similar devices as growth in these markets slows.
Samsung’s focus is on manufacturing generic versions of biological medicines (biologics) and providing biomanufacturing outsourcing for big pharma, helping to provide these effective drugs at a lower cost.
Tae-Han Kim, president of Samsung Biologics, told the Financial Times:
Biopharmaceutical companies are good for sales, and biotech companies for innovation, but neither is good for manufacturing.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.Company Profile – free sample
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
A new $740m biologic plant, Samsung’s third, will provide the capacity for the company to become the leading producer by volume of biologics, which are drugs grown from cells.
This necessitates a more complex manufacturing process than typical drugs, but the upside is that biologics are more effective towards certain diseases.
Samsung’s experience in building semiconductor plants has allowed it to streamline the timescale and cost of building its biologic plants.
Samsung BioLogics currently has agreements with six clients, including Roche and Bristol-Myers Squibb, for nine different products.
As of April it is also in negotiations to manufacture drugs for more than 15 international pharmaceutical companies, as it looks to expand in the growing industry.
In July, Merck and Samsung Bioepis began selling a less expensive alternative version of Johnson & Johnson’s rheumatoid arthritis drug Remicade in the US, a move that should accelerate price reductions for the big-selling medicine.
The US and Korean drugmakers said they would sell their version, to be called Renflexis, at a 35 percent discount to Johnson & Johnson’s top-selling medicine – or about $735 for a 100 milligram dose.